Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.50 |
| ▸ | MAPK3 | P27361 | 6/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.44 |
| ▸ | INSR | P06213 | 4/20 | 0.44 |
| ▸ | IGF1R | P08069 | 3/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 6/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30044353 | 1.00 | PLK1 (0.50) | PLK1MAPK3ALKINSRIGF1R | |
| SCHEMBL25139867 | 0.99 | PLK1 (0.49) | PLK1MAPK3ALKINSRIGF1R | |
| SCHEMBL30044360 | 0.95 | ALK (0.50) | PLK1MAPK3ALKINSRIGF1R | |
| SCHEMBL25139843 | 0.95 | ALK (0.50) | PLK1MAPK3ALKINSRIGF1R | |
| SCHEMBL30045137 | 0.94 | EGFR (0.48) | PLK1MAPK3ALKINSRIGF1R | |
| SCHEMBL25139873 | 0.94 | EGFR (0.48) | PLK1MAPK3ALKINSRIGF1R | |
| SCHEMBL30044565 | 0.93 | PLK1 (0.51) | PLK1MAPK3ALKINSRIGF1R | |
| SCHEMBL23606810 | 0.93 | PLK1 (0.51) | PLK1MAPK3ALKINSRIGF1R | |
| SCHEMBL25139852 | 0.92 | PLK1 (0.50) | PLK1MAPK3ALKINSRIGF1R | |
| SCHEMBL25139862 | 0.91 | ALK (0.42) | PLK1MAPK3ALKINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125046-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-04-20 | — | — | US | disclosed |
| WO-2021129561-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125046-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | FGFR4, FGFR1, WEE1 | PLK1 250/4885MAPK3 809/4885ALK 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.